CDIO · Cardio Diagnostics Holdings, Inc. · Financials

$2.03 +0.05 (+2.53%) At close · Sep 11

Market Cap

$6.01M

2.96M

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Pull these statements through the financial statements API or MCP →

Revenue

$14.83K -57.5%

FY2025

Net Income

-$6.5M +22.5%

FY2025

Operating Margin

-43737.46% -19759.6pp

FY2025

Diluted EPS

-$3.71 +60.3%

FY2025

Operating Cash Flow

-$5.73M -14.7%

FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	TTM	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	+149.9%	—	—	$14.45K	$14.83K	$34.89K	$17.07K	$950	$901
Research & Development	+151.2%	—	—	$636.6K	$641.21K	$227.97K	$145.18K	$40.45K	$31.47K
Selling & Marketing	+102.2%	—	—	—	$766.89K	$1.23M	$158.51K	$92.7K	$103.32K
General & Administrative	+4.5%	—	—	—	$5.03M	$6.92M	$6.94M	$4.4M	$470.56K
Amortization of Intangibles	-30.7%	—	—	—	$5333	$16K	$16K	$16K	—
Depreciation & Amortization	+59.8%	—	—	—	$65.23K	$19.74K	$19.18K	$16K	$16K
Total Operating Expenses	+12.6%	—	—	$6.47M	$6.5M	$8.4M	$7.26M	$4.55M	$621.35K
Operating Income	—	—	—	-$6.46M	-$6.48M	-$8.37M	-$7.24M	-$4.55M	-$620.45K
Operating Margin	—	—	—	—	-43737.46%	-23977.86%	-42440.43%	-478784.32%	-68862.15%
EBITDA	—	—	—	—	-$6.42M	-$8.35M	-$7.22M	-$4.53M	-$604.45K
Interest Expense	—	—	—	$12.3K	$14.8K	$18.64K	$6.74M	—	—
Interest Income	—	—	—	$572	$712	$1064	$1068	—	—
Other Non-Operating Income	—	—	—	-$11.73K	-$14.09K	-$17.58K	-$1.13M	-$112.53K	—
Pretax Income	—	—	—	-$6.47M	-$6.5M	-$8.38M	-$8.38M	-$4.66M	-$620.45K
Income Tax	—	—	—	$0	—	—	—	$0	$0
Net Income	—	—	—	-$6.47M	-$6.5M	-$8.38M	-$8.38M	-$4.66M	-$620.45K
Net Margin	—	—	—	—	-43832.49%	-24028.24%	-49087.81%	-490630%	-68862.15%
Net Income Available to Common Stockholders	—	—	—	$5.4M	—	—	—	$4.66M	$620.45K
EPS (Basic) USD/shares	—	—	—	-$2.91	-$3.71	-$9.35	-$19.80	-$45.30	-$15.90
EPS (Diluted) USD/shares	—	—	—	-$2.91	-$3.71	-$9.35	-$19.80	-$45.30	-$15.90
Shares Outstanding (Basic Avg) shares	+157.2%	—	—	—	1.75M	896.42K	422.84K	102.92K	38.77K
Shares Outstanding (Diluted Avg) shares	+157.2%	—	—	—	1.75M	896.42K	422.84K	102.92K	38.77K

Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Debt Profile

Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.

Debt data is being processed. Please check back later.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

—

Peer median 2.06×

EV/EBIT

—

P/E (TTM)

—

Peer median 0.24×

Peer medians compare against the 171 similar-size Biotechnology companies (of 536 listed).

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component	FY2025	FY2024
Reportable Segments	$14,825	$34,890

By Product & Service (USD)

Component	FY2025	FY2024
Product Test Sales	$14,825	$34,890

Key facts CIK 1870144 CUSIP 14159C202 13F (30d) 5 filings 5 filers Visit website Investor relations